The Hong Kong-listed cancer biotech said this morning that anti-PD-L1 inhibitor sugemalimab given in combination with chemotherapy showed “statistically significant and clinically meaningful” improvements in both progression-free survival (PFS) and overall survival (OS) in previously-untreated patients with unresectable locally advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (ESCC).
The result is good news for Pfizer, which has exclusive marketing rights to the drug in mainland China under an agreement signed in 2020.
